Top 50 Biotechnology Startup Investors in France (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Bpifrance
VC Fund
|
71 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $658k–$35M |
|
Seventure Partners
VC Fund
|
28 | France, United States, Germany | Series A, Series B | Biotechnology, Software, Health Care | $3.1M–$65M |
|
Kurma Partners
VC Fund
|
28 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.3M–$80M |
|
GO CAPITAL
VC Fund
|
26 | France, Canada, Israel | Seed, Series A | Biotechnology, Software, Health Care | $516k–$10M |
|
Sofinnova Partners
VC Fund
|
25 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
Karista
VC Fund
|
23 | France, United States, Finland | Seed, Series A, Series B | Software, Biotechnology, Health Care | $713k–$43M |
|
Elaia
VC Fund
|
21 | France, United States, Spain | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.1M–$38M |
|
Auriga Partners
VC Fund
|
17 | France, United States, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $2.2M–$33M |
|
Omnes Capital
VC Fund
|
16 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$43M |
|
Idinvest Partners
VC Fund
|
16 | France, United States, Spain | Series B, Series A | Biotechnology, Health Care, Software | $3.3M–$66M |
|
Angels Santé
VC Fund
|
13 | France, India, United States | Seed, Angel | Health Care, Biotechnology, Medical Device | $658k–$3.4M |
|
Sofimac Investment Managers
VC Fund
|
12 | France, Italy, Austria | Seed, Series A | Biotechnology, Health Care, Manufacturing | $274k–$15M |
|
AQUITI Gestion
VC Fund
|
11 | France, United States | Series A, Seed | Biotechnology, Software, Manufacturing | $170k–$18M |
|
AdBio partners
VC Fund
|
10 | France, Spain, Belgium | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $2.2M–$37M |
|
Cap Innov'Est
VC Fund
|
9 | France, United States | Seed, Series A | Biotechnology, Medical, Health Care | $549k–$7.7M |
|
Inserm Transfert Initiative
VC Fund
|
8 | France, Switzerland, United States | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.1M–$60M |
|
Galia Gestion
VC Fund
|
8 | France, United States | Series A, Seed | Software, Manufacturing, Biotechnology | $531k–$6.9M |
|
Pontifax
VC Fund
|
8 | United States, Israel, France | Series A, Series B, Series C | Biotechnology, Health Care, Pharmaceutical | $4M–$104M |
|
Sham Innovation Santé
VC Fund
|
7 | France | Series B, Series A | Biotechnology, Medical Device, Medical | $5.7M–$80M |
|
IRDI
VC Fund
|
7 | France | Series A, Seed | Health Care, Software, Biotechnology | $1.6M–$22M |
|
Crédit Agricole
VC Fund
|
7 | France, United States, Italy | Seed, Debt Financing | Energy, Software, Health Care | $768k–$1.3B |
|
IRDI SORIDEC Gestion
VC Fund
|
7 | France, Brazil, Singapore | Seed, Series A | Software, Biotechnology, Medical | $1.6M–$13M |
|
WiSEED
VC Fund
|
7 | France | Seed, Equity Crowdfunding | Software, Manufacturing, Biotechnology | $384k–$3.3M |
|
Meusinvest (Noshaq)
VC Fund
|
7 | Belgium, France, Germany | Series A, Seed | Biotechnology, Health Care, Medical | $137k–$16M |
|
M Capital Partners
VC Fund
|
6 | France, United States, Canada | Seed, Series A | Health Care, Software, Food and Beverage | $1.1M–$7.7M |
|
UI Investissement
VC Fund
|
6 | France, Spain, Canada | Private Equity, Series A, Seed | Manufacturing, Software, Health Care | $1.5M–$49M |
|
SOSV
VC Fund
|
6 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Paca Investissement
VC Fund
|
6 | France | Seed, Series A | Software, Internet, Manufacturing | $329k–$9.2M |
|
XAnge
VC Fund
|
6 | France, Germany, Belgium | Series A, Seed, Series B | Software, SaaS, E-Commerce | $1.1M–$60M |
|
Normandie Participations
VC Fund
|
6 | France | Seed, Series A | Biotechnology, Software, Health Care | $439k–$11M |
|
Caisse d’Epargne
VC Fund
|
6 | France | Debt Financing, Seed | Software, Health Care, Biotechnology | $400k–$285M |
|
Demeter
VC Fund
|
6 | France, Germany, Slovenia | Seed, Series A | Manufacturing, Software, AgTech | $1.6M–$27M |
|
BNP Paribas
VC Fund
|
6 | France, United Kingdom, United States | Debt Financing, Post-IPO Debt | Financial Services, Information Technology, Software | $58M–$3.8B |
|
Crédit Mutuel Innovation
VC Fund
|
6 | France, United States, Canada | Series A, Series B | Software, Health Care, Biotechnology | $3.3M–$43M |
|
Octalfa
VC Fund
|
6 | France | Seed, Series A | Health Care, Biotechnology, Medical | $658k–$4.6M |
|
CEA Investissement
VC Fund
|
6 | France, Canada, United States | Seed, Series A | Manufacturing, Biotechnology, Semiconductor | $796k–$21M |
|
Supernova Invest
VC Fund
|
5 | France, United States, Israel | Series A, Series B | Manufacturing, Health Care, Medical Device | $6M–$58M |
|
Galion.exe
VC Fund
|
5 | France, The Netherlands, Germany | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Biotechnology | $1.1M–$23M |
|
Emertec
VC Fund
|
5 | France, Canada, United States | Series A, Series B | Energy, Software, Electronics | $1.4M–$15M |
|
Starquest Capital
VC Fund
|
5 | France, Singapore, The Netherlands | Seed, Series A | Software, Manufacturing, Information Technology | $288k–$9.9M |
|
Kima Ventures
VC Fund
|
5 | France, United States, United Kingdom | Seed, Pre-Seed, Series A | Software, SaaS, Artificial Intelligence | $549k–$16M |
|
Pureos Bioventures
VC Fund
|
5 | France, Switzerland, The Netherlands | Series A, Series B, Series C | Biotechnology, Therapeutics, Medical | $6.6M–$125M |
|
Entrepreneurs First
VC Fund
|
5 | United Kingdom, United States, India | Pre-Seed, Seed, Series A | Artificial Intelligence, Software, Information Technology | $100k–$220M |
|
Andera Partners
VC Fund
|
5 | France, United States, Germany | Series B, Private Equity | Biotechnology, Health Care, Medical | $14M–$247M |
|
Aurinvest
VC Fund
|
4 | France, United States, Belgium | Series A, Series B | Software, E-Commerce, Biotechnology | $1.4M–$16M |
|
BNP Paribas Développement
VC Fund
|
4 | France, Germany, The Netherlands | Series A, Seed | Software, Health Care, Information Technology | $2M–$23M |
|
Nord France Amorcage
VC Fund
|
4 | France, United States | Seed, Series A | Software, Information Technology, Medical | $329k–$25M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$88M |
|
KREAXI
VC Fund
|
4 | France, Italy, Switzerland | Seed, Series A | Software, Information Technology, SaaS | |
|
IXO Private Equity
VC Fund
|
4 | France, United States, Canada | Private Equity, Series A | Health Care, Manufacturing, Biotechnology | |
| Access all 852 investors in France Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 989
- Round size: Seed $658k–$6.4M; Series A $2.5M–$35M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Kayrros — Kayrros is the leading advanced data analytics company that helps traders, investors, operators and governments make better decisions.
- Callyope — Callyope is building the first speech-based foundational model to monitor mental health symptoms through low-touch smartphone interactions.
- ErVimmune — Our team is focused on bringing breakthrough immunotherapies in unmet medical needs for cancer patients. Check our work!
Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 213
- Round size: Series A $3.1M–$24M; Series B $3.3M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Karmen — Karmen offers revenue-based financial solutions such as venture capital and loans to accelerate business growth for SaaS companies.
- Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 128
- Round size: Seed $2.3M–$13M; Series A $3.8M–$74M; Series B $8.8M–$80M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
- Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: France, Canada, Israel
Investor stats
- Total investments: 130
- Round size: Seed $516k–$6.6M; Series A $2.1M–$10M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Episto — Episto helps you collect ultra-authentic insights from your targets, anywhere in the world, simply and instantly
- AISPRID — AISPRID is a robotic company that manufactures autonomous robots for soft fruit picking.
- Axomove — Axomove is an e-health app that specializes in video physical exercises.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: France, United States, Finland
Investor stats
- Total investments: 144
- Round size: Seed $713k–$6.6M; Series A $1.2M–$15M; Series B $2.5M–$43M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- CYSEC — Secure your sensitive data in the cloud and in the edge with ARCA Trusted OS and open the door to innovation with confidential computing.
- Stootie — Stootie is a buyer-focused classifieds platform. It's mobile. It's local. And it's quick. Really quick!This is the tool you use to get that phone power outlet you forgot when you're working in a Starbucks. Or pretty much anything else. Anywhere. Anytime.The keywords of Stootie are : marketplace, P2P business, local,mobile, realtime, platform.Stootie is currently available on iOS and Android.
- Exotrail — Exotrail is an end-to-end space mobility operator. Our mission is to enable small satellites to move in space, optimise their deployment, increase their service performance, and reduce space pollution.
Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: France, United States, Spain
Investor stats
- Total investments: 210
- Round size: Seed $1.1M–$9.9M; Series A $2.2M–$27M; Series B $4.2M–$38M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Elevo — Elevo is a Paris-based performance management platform.
- Vibe — Advertise your brand on CTV & OTT content with Vibe's self-serve ad platform to target hundreds of channels & networks and reach millions of households.
- Traefik Labs — Cloud-native, GitOps-driven API runtime solutions for demanding DevOps and Platform Engineers with diverse use-cases, environments, and deployment models.
Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 128
- Round size: Series A $2.2M–$14M; Series B $3.8M–$33M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Amplitude — Amplitude is a leading manufacturer of femtosecond lasers. We are laying the foundations for advances in science, industry, and health care.
- Pherecydes Pharma — Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.
- Median Technologies — We harness the power of Imaging Phenomics to contribute to the development of next generation treatments and care strategies for patients in need.
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 175
- Round size: Series A $3.5M–$38M; Series B $4.4M–$43M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
- Sekoia.io — Sekoia.io provides cyber teams with a SOC platform that can respond to security incidents, regardless of the attack surface.
- Amakem — Easy, affordable options for you to obtain the domain you want. Safe and secure shopping.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A
- Geography: France, United States, Spain
Investor stats
- Total investments: 252
- Round size: Series A $3.3M–$24M; Series B $7.8M–$66M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $88M in 2021
Portfolio highlights
- Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
- Glovo — Glovo delivers the best products of your city in less than 1 hour
- Stanley Robotics — Stanley Robotics is a DeepTech business helping the transportation and logistics industries digitalise and robotise outdoor operations.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Angels Santé is the leading French Business Angel Network solely dedicated to Healthcare investments.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Seed, Angel
- Geography: France, India, United States
Investor stats
- Total investments: 34
- Round size: Seed $1.1M–$3.4M; Angel $658k–$1.3M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Abcely — Abcely is a biotech firm that is working on a novel anti-cancer medication.
- Odimma — Empowering personalized immunotherapy to treat cancer
- AUSTRAL Dx — Austral Dx develops contactless AI technology for rapid cardiopulmonary diagnostics, helping clinicians identify life-threatening conditions faster in emergency care.
Acteur incontournable du capital risque de proximité, SOFIMAC PARTNERS accompagne depuis maintenant plus de 30 ans les PME régionales dans le financement de leur développement à moyen / long terme. Répondant à la problématique de sous capitalisation des PME françaises, SOFIMAC PARTNERS intervient en fonds propres aux côtés des chefsd’entreprises quelle que soit leur problématique : Création, Développement, Transmission. Gérant 200 M€ d’actifs au travers de 16 fonds (FCPR, FCPI, SCR, FIP,…), notre groupe réalise ses investissements sur une grande variété de secteurs, couvrant aussi bien les activités traditionnelles que technologiques (chimie verte, éolien, chaudronnerie aéronautique, e-commerce, édition de logiciel, médecine nucléaire etc…)
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Seed, Series A
- Geography: France, Italy, Austria
Investor stats
- Total investments: 73
- Round size: Seed $274k–$2M; Series A $1.6M–$15M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Ultrawatt — Ultrawatt is a mission-driven startup to improve urban architecture while making a beneficial social and environmental effect.
- Mob-Energy — Mob-Energy is a privately held company specializing in the development of mobile and innovative charging solutions. It designs autonomous charging robots capable of moving energy where it is needed, optimizing the site's existing infrastructure. The company was founded in 2018 and is headquartered in Villeurbanne, Auvergne-Rhône-Alpes.
- Snowleader — Votre boutique en ligne (qui sent bon le reblochon) spécialiste des sports d’hiver, outdoor et street.
Floated in 1998, thanks to the local authority "Conseil Régional d’Aquitaine" and the "Caisse des dépôts", our venture, growth and LBO funds (Aquitaine Amorçage, ACI, Aqui-Invest) now benefit from the support of public and private influential shareholders and sponsors.Up to now, AQUITI GESTION has invested in more than 200operations contributing to the creation and development of about 150 companies and thousands of jobs.Currently, ACI and Aqui-Invest manage a portfolio gathering 50 companies which revenues scale from 0 € (early stage) to 30 M€.
Show more...Investment focus
- Industry: Biotechnology, Software, Manufacturing
- Stage:Series A, Seed
- Geography: France, United States
Investor stats
- Total investments: 55
- Round size: Seed $170k–$5.8M; Series A $849k–$18M
- Lead/follow: 22% lead, 78% follow
- Last fund: May invest from a new fund soon — raised $6.4M in 2010
Portfolio highlights
- Speeral — Speeral est la plateforme SaaS qui automatise le cycle complet de vente sur les marketplaces C2C et vous permet de tirer profit du canal.
- Aquassay — Aquassay assists you with improving the industrial and environmental performance of all your water usage (supply, production, discharge).
- Amédia Solutions — Amédia Solutions is an IT service provider and telecom operator. It is a local player specializing in B to B IT and telecoms. It has thus been able to forge various strong partnerships with publishers, manufacturers, infrastructure operators, security specialists to offer the best of IT and telecommunications.
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: France, Spain, Belgium
Investor stats
- Total investments: 25
- Round size: Seed $2.2M–$9.3M; Series A $19M–$37M
- Lead/follow: 48% lead, 52% follow
- Last fund: Likely still investing — raised $116M in 2021
Portfolio highlights
- DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
- AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
- Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Cap Innov’Est is a 36M€ tri-regional fund dedicated to investments in young innovative start-ups. Cap Innov’Est was launched in July 2014 and has already invested in 13 start-ups. Cap Innov’Est is supported by Fonds National d’Amorçage, the 3 Regions Alsace, Bourgogne and Franche-Comté, SAFIDI, caisses d’épargne d’Alsace etBourgogne/Franche-Comté, BNP Paribas et CIFC
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: France, United States
Investor stats
- Total investments: 18
- Round size: Seed $549k–$2.7M; Series A $7.5M–$7.7M
- Lead/follow: 44% lead, 56% follow
- Last fund: May invest from a new fund soon — raised $42M in 2014
Portfolio highlights
- PeptiMimesis — PeptiMimesis is a strategic partner in the design, the discovery and the early development of transmembrane therapeutic peptides. Our innovative approach enables the identification of peptidomimetic candidates interfering with the hetero- and/or the homodimerization of target receptors.PeptiMimesis will develop its pipeline against keytargets in the fields of oncology, immuno-oncology and immune disease and is open to initiate collaboration with pharma partners on receptors of interest.
- Inoviem Scientific — Our groundbreaking label-free technologies enable you to detect and identify the clinical power of, and weaknesses in, your compound from early-stage pre-clinical R&D through to clinical trials
- Rhythm Diagnostic Systems — Many of our team have worked together on different projects and in different companies over the last 30-plus years. We are experienced technology, medical, health care and biotech professionals, with long, successful histories in Silicon Valley and elsewhere.
Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: France, Switzerland, United States
Investor stats
- Total investments: 21
- Round size: Seed $2.7M–$3.6M; Series A $1.1M–$35M; Series B $2.2M–$60M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
- VectivBio — Explore Ironwood Pharmaceuticals' commitment to GI health with innovative therapies, patient-focused research, and a vision to improve digestive disease treatment.
- Aelis Farma — Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways.Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.
Galia Gestion is a private equity and venture capital firm. GALIA Gestion is a “management company” approved by the AMF, with majority shareholder Alliance Entreprendre.
Show more...Investment focus
- Industry: Software, Manufacturing, Biotechnology
- Stage:Series A, Seed
- Geography: France, United States
Investor stats
- Total investments: 55
- Round size: Seed $531k–$2.9M; Series A $849k–$6.9M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $21M in 2013
Portfolio highlights
- Wizaly — Wizaly's ambition is to help advertisers understand the impact of their online & offline marketing channels across all conversions, helping clients improve the ROI of their marketing budgets by up to 30%.The Wizaly platform applies its algorithmic attribution technology to provide a holistic and unbiased vision of campaigns performancestogether with actionable optimization recommendations.
- Agenium — Agenium offers career perspectives in an international and tech environment. They offer this through the specific expertise of their business units. They offer solutions to the business and of the defense, industry, and space sectors.
- Germitec SAS — Germitec is a world leader in UV-C high-level disinfection. Fast, safe, chemical-free, one-button UV-C high-level disinfection for ultrasound probes.
Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Series B, Series C
- Geography: United States, Israel, France
Investor stats
- Total investments: 106
- Round size: Series A $4M–$95M; Series B $20M–$100M; Series C $12M–$104M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $14M in 2020
Portfolio highlights
- Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
- Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
- Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
Sham Innovation Sante is an innovation capital vehicle controlled and held by Sham, a mutual insurer specialized in risk management for health care, social welfare and community health organizations. Advised by Turenne Capital, Sham Innovation Sante's mission is to support innovative businesses in the health care sector through the growth anddevelopment phases of their life cycle.
Show more...Investment focus
- Industry: Biotechnology, Medical Device, Medical
- Stage:Series B, Series A
- Geography: France
Investor stats
- Total investments: 16
- Round size: Series A $5.7M–$74M; Series B $9.9M–$80M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Cairdac — Cairdac is a manufacturer of autonomous leadless pacing transcatheter system capable of powering the device with no battery-life limitation.
- Therapixel — Therapixel is one of the leading French software companies specializing in artificial intelligence applied to medical imaging.
- Germitec SAS — Germitec is a world leader in UV-C high-level disinfection. Fast, safe, chemical-free, one-button UV-C high-level disinfection for ultrasound probes.
IRDI Gestion aims to participate in the economic growth and job creation in their regions. For this, their teams create a real partnership with the companies they accompany, based on a relationship of trust and proximity.IRDI Gestion currently manages €150 million and has financial tools able to accompany the Southwest SMEs in the creationphase, development or transmission, with intervention tickets from equity € 100000 to € 5000000.Precursor of regional investment capital of the Southwest, with a presence of over 35 years, the IRDI Group consists of 3 SCR:- IRDI, created in 1981 to foster industrial growth companies based in the South West of France- MPcroissance, created in 1996 to assist small businesses in Midi-Pyrénées- IRDInov, created in 2012 under the leadership of the National Seed Fund (under the PIA) to fund the initiation of innovative companiesIn 2015, the management company IRDI Gestion, approved by the AMF, was formed to structure the group and bring new development projects.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Seed
- Geography: France
Investor stats
- Total investments: 43
- Round size: Seed $1.9M–$9.2M; Series A $1.6M–$22M
- Lead/follow: 14% lead, 86% follow
Portfolio highlights
- REEV — REEV motorizes medical orthoses to help millions of people affected by gait disorders to walk, stand, sit and climb stairs with greater ease every day.
- Starfish Bioscience — STARFISH Bioscience focuses on the creation and development of microbiological solutions for agriculture and vineyards. Our objective is to regenerate soils by restoring their microbiomes, increasing sustainability and productivity while minimizing environmental impact. We are dedicated to improving humanity's well-being and preserving theearth by inventing technologies that address the future difficulties of global agriculture.
- Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Credit Agricole is a banking corporation with focuses on corporate and investment banking, retail banking, and savings management. Crédit Agricole Group is a responsible, helpful bank serving 49 million customers, 7.4 million mutual shareholders, and 1.2 million shareholders. Crédit Agricole Group supports its customers in their plans and projectsin France and around the world, through its operations in all segments of the market including insurance, real estate, payment systems, asset management, leasing and factoring, consumer finance, and corporate and investment banking. Crédit Agricole also stands out for its dynamic, innovative corporate social responsibility policy serving the economy. This policy is based on a pragmatic approach that permeates throughout the entire Group and engages all its employees. Its recent inclusion in the Vigeo-NYSE Euronext extra-financial indices is recognition of this engagement.
Show more...Investment focus
- Industry: Energy, Software, Health Care
- Stage:Seed, Debt Financing
- Geography: France, United States, Italy
Investor stats
- Total investments: 131
- Round size: Seed $768k–$4.4M; Debt Financing $1.6M–$1.3B
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Fortum — By providing our customers and the Nordic energy system with a supply of reliable energy, we aim to power a world where people, businesses, and nature thrive together. With respect for the environment, decades of expertise and smart solutions, we strive to meet our customers' needs.
- FlowPay — Open banking & payment solutions. FlowPay supporta la tua azienda nei flussi di incasso e pagamento con soluzioni innovative integrabili via API.
- EuroGroup Laminations — We develop and produce stators and rotors solutions for the energy transition, guaranteeing maximum efficiency and sustainability on a global scale.
IRDI SORIDEC Gestion is a portfolio management company that supports startups, SMEs, and ETIs in the greater South-West of France with equity capital at all stages of development.
Show more...Investment focus
- Industry: Software, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: France, Brazil, Singapore
Investor stats
- Total investments: 51
- Round size: Seed $1.6M–$5.8M; Series A $3.7M–$13M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Donecle — Automated aircraft inspections by drone for airlines and MRO. Donecle makes aircraft maintenance faster, safer and more reliable. Our unique technology combines 100% automated drone and image analysis algorithms to detect defects, lightning strikes, evaluate paint wear and check placards.
- Sim&Cure — Providing Physicians with advanced endovascular treatment solutions for a better Patient Care
- DiappyMed — DiappyMed specializes in developing platforms to calculate insulin dosages.
Wiseed is a crowdfunding platform that enables its users to invest in SMEs and enterprises. The platform offers investments for startups, real-estate firms, social innovation and renewable energy projects, and agriculture firms. It was founded in 2008 by Nicolas Seres and Thomas Merquiol and is based in Toulouse.
Show more...Investment focus
- Industry: Software, Manufacturing, Biotechnology
- Stage:Seed, Equity Crowdfunding
- Geography: France
Investor stats
- Total investments: 30
- Round size: Seed $384k–$3.3M; Equity Crowdfunding $466k–$2.7M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Leasi — Leasi delivers a forward-thinking rental and resource management system for companies that engage in internal or external distribution of machinery. This is achieved through an ecosystem that emphasizes the excessive use of data and datasharing, with a focus on user experience. Our goal is to create a simpler, more streamlined, and more efficientworkday for industry players by leveraging the power of data and collaboration within the ecosystem to ultimately reduce emissions, increase efficiency and enhance profitability.
- Aéronde — The Aéronde is an innovative electric airship with a toroidal shape (giant donut) of 15 meters in diameter, designed to offer a silent, energy-efficient flight with very low environmental impact. Inflated with approximately 400 m³ of helium, it can carry up to two people and equipment, with a payload of 200 kg .
- Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 76
- Round size: Seed $137k–$6M; Series A $3.3M–$16M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
M Capital is an independent investment company with +€500m AuM. A unique hub where entrepreneurs can have an equity finance and quasi-equity as well as a permanent support to accelerate their growth. In 2020, M Capital has funded over 200 French companies.
Show more...Investment focus
- Industry: Health Care, Software, Food and Beverage
- Stage:Seed, Series A
- Geography: France, United States, Canada
Investor stats
- Total investments: 108
- Round size: Seed $1.1M–$5.2M; Series A $3.3M–$7.7M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Hakbah — Hakbah is a Fintech startup focusing on an alternative financial saving. Hakbah is modernizing financial saving via its intelligent platform by offering a comprehensive one-stop-shop solution for Savings Groups to initiate, manage, join, and pay directly within the mobile app.
- Demether — Demether is a DeFi protocol that works to enable zero-cost access to TVL for blockchains.
- The Sanctuary Group — The Sanctuary Group provides aqua-cycling, indoor cycling, boxing bootcamp, yoga, dance cardio, HIIT workouts, and kids’ swim classes.
Since 1967, the UI brand embodies a partnership with companies. Actor of the economy, UI has accompanied more than 120 SMEs over the last fifteen years, investing more than 550m € and giving substance to their development projects. Combining experience and corporate culture, UI has established itself as an involved and independent partner, able tocount on its shareholder leaders to favor, independently, the sustainable performance of the SMEs it accompanies.
Show more...Investment focus
- Industry: Manufacturing, Software, Health Care
- Stage:Private Equity, Series A, Seed
- Geography: France, Spain, Canada
Investor stats
- Total investments: 98
- Round size: Seed $1.5M–$7.1M; Series A $2.9M–$33M; Private Equity $3.1M–$49M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely still investing — raised $37M in 2021
Portfolio highlights
- DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
- Fizimed — Fizimed has made the choice to develop the EMY perineal probe with recognized health professionals. The probe is connected to a mobile app and associated with custom exercises. The probe captures the contractions of the perineal muscles in real time to allow the patient to do 5-minute exercises through fun games (jumping obstacles, jumping ...) sothat she remains motivated. The patient can follow her results as well as her progress in the application and unlock new universes according to the points obtained. Much of the effort of Fizimed's technical teams is focused on balancing a product, combining the quality and safety of a medical device, with a fun application to empower each woman. One goal: the simplicity of the product and the interface for home use.Beyond the product, the Fizimed team is committed to the fight against taboos related to urinary incontinence problems affecting one in ten women. She wants to "demystify" this topic so that every woman can find her adapted solution. An EMY community is being born on social networks in which the feminine hassles are put into images and discussed with humor, while talking about innovations that can simplify their daily lives.In summary, EMY by Fizimed is the connected and fun medical probe that allows women wishing to regain control of their perineum to do their home exercises. It was developed by a dynamic Alsatian start-up whose ambition is to remove taboos on a public health issue.
- Fungu'it — A new generation of flavor ingredients for healthy, sustainable, and accessible food.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Paca Investissement is specializes in investing in startups and developmental stages. The fund invests in the Provence-Alpes-Côte d'Azur (PACA) region.
Show more...Investment focus
- Industry: Software, Internet, Manufacturing
- Stage:Seed, Series A
- Geography: France
Investor stats
- Total investments: 73
- Round size: Seed $329k–$1.6M; Series A $411k–$9.2M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- GANGZ — Gangz is the first digital platform for talent recruitment: Models, hosts, extras and actors.
- SailEazy — The SailEazy community offers all sailing enthusiasts the choice of freedom. A shared professional fleet, bases between the Atlantic and the Mediterranean ... discover a disruptive and innovative way of navigation. Throughout the year, 7 days / 7 and 24 hours a day, you can book and discover the high-performance sailboats of a professionalfleet, entirely managed by SailEazy. Subscriber, or punctual browser, autonomous or not, you have the choice. You freely determine your niche of reservation, without constraint time or duration, you choose your base of departure and your sailboat, according to your program (short exit, cruise, regatta, coastal, wide ...). Hourly pricing includes a 360 ° service keychain beyond the cost of the lease, including insurance, fuel, cleaning and equipment. Compulsive veiled, expert or contemplative, all members of the community have their way of navigating.
- C4Diagnostics — Dana69 adalah tempat penyedia link login game online yang bisa di mainkan dengan menggunakan smartphone android dan iphone dan bisa melakukan top up slot dana 10k atau slot deposit dana 10k selalu online 24 jam.
XAnge is a Franco-German team of venture capital investors that manages €450 million and invests in digital, deeptech, and impact startups.It is the innovation brand of the Siparex group, a major player in French private equity. XAnge is a key European investor in early-stage startups and is looking for game-changing startups and entrepreneurswho rock the code[s].The Paris, Ile-de-France-located company was founded in 2004.
Show more...Investment focus
- Industry: Software, SaaS, E-Commerce
- Stage:Series A, Seed, Series B
- Geography: France, Germany, Belgium
Investor stats
- Total investments: 210
- Round size: Seed $1.1M–$8M; Series A $3M–$22M; Series B $6M–$60M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $234M in 2021
Portfolio highlights
- Tomorro — Leeway helps you reduce the time spent on contract management and gives you more control and visibility over legal and financial risks.
- Request Finance — A suite of financial tools to make your life easier - crypto organizations & freelancers use Request for invoices, expenses, payroll or accounting.
- POLLEN Metrology — The revolution of artificial intelligence for high performance materials. Accelerate the time to yield of new materials and processes.
Normandie Participations is a venture capital fund that co-invests in companies based in Normandy. It invests through equity and quasi-equity in small and medium-sized enterprises. The firm was founded in 2016 and is based in Colombelles, France.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: France
Investor stats
- Total investments: 30
- Round size: Seed $439k–$2.4M; Series A $1.6M–$11M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- RMAN Sync — RMAN Sync is the collaborative SRM by AI and deep learning that develops synergies between purchasing, supply chain, and trade.
- Loop Dee Science — Loop Dee Science is a DNA startup that makes molecular biology diagnostics. They develop and manufacture field genetic analysis kits for the detection of pathogen DNA and RNA. Their automatic field analysis device is a multi-spectral analysis device that provides local output and can also be connected via USB or Bluetooth.
- Good Motors agency — Good Motors agency offers self-service motorcycle rentals near train stations and airports in France's most beautiful regions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Caisse d’Epargne is a cooperative bank that supports all economic players. It shares its values of social responsibility and humanism with its member customers. It is committed to the heart of the regions, the 15 regional savings banks are involved on a daily basis in their clients' projects and provide them with tailor-made solutions.Ithas now had 4.8 million members and 20.6 million customers, managed by 4,182 bank branches and the My Online Banker branch.It was created in 1818 and is headquartered in Paris, France.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Debt Financing, Seed
- Geography: France
Investor stats
- Total investments: 50
- Round size: Seed $400k–$4.4M; Debt Financing $439k–$285M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Hexa — eFounders partners with talented co-founders to build the future of product-led SaaS.
- Leanspace — Today, space organizations need to build and manage increasingly complex ground software infrastructures: to design, integrate and operate their assets. To do so, they can rely on off-the-shelf systems (COTS) but lose control over their tools, or build everything from scratch which is slow and consumes lots of resources.Leanspace brings a new wayto build space software. We provide all the generic functions, easily consumable as-a-service, via APIs. The platform enables organizations to build all their systems in-house, but only developing the functionalities they need. This drastically reduces time & costs, keeps them in control, and boosts competitiveness.Leanspace-powered systems are integrated, collaborative and digital. Don’t reinvent the wheel, transform your business!
- Miura Simulation — Miura helps engineers take control of their data, connect tools, reduce vendor friction, and lay the foundation for scalable AI.
Demeter is a major player in venture capital and private equity for the energy and ecological transition. They invest from 500 K€ to 30 M€ to support companies at all stages of their development: innovative startups, high growth SMEs and infrastructure projects.
Show more...Investment focus
- Industry: Manufacturing, Software, AgTech
- Stage:Seed, Series A
- Geography: France, Germany, Slovenia
Investor stats
- Total investments: 89
- Round size: Seed $1.6M–$4.6M; Series A $6.6M–$27M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Lixo — Lixo develops software solutions to improve the performance of recycling companies, from waste collection to sorting and recyling
- SWEETCH Energy — SWEETCH Energy is developing a breakthrough technology in the field of salinity gradient power harvesting.
- BeFC Bioenzymatic Fuel Cells — Miniature batteries are complex, expensive and unecological to collect and recycle. Our thin, light-weight and flexible paper-based biofuel cells are biodegradable, environmentally friendly and economically viable.
BNP Paribas provides banking, financing, investment, savings, and protection solutions. The Group's three operational divisions are mobilized to support each type of clientele in their growth and development projects including corporate and institutional banking, commercial, personal banking, investment and protection services. The companyprovide financing and investment services to retail customers, associations, businesses, and corporations.
Show more...Investment focus
- Industry: Financial Services, Information Technology, Software
- Stage:Debt Financing, Post-IPO Debt
- Geography: France, United Kingdom, United States
Investor stats
- Total investments: 189
- Round size: Post-IPO Debt $58M–$1.9B; Debt Financing $77M–$3.8B
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- PHENIX — Phenix, la solution anti-gaspillage pour les professionnels. Leader de la gestion des invendus en Europe : maximisez la valeur de vos surplus.
- Proxymity — Announcing our Newest Partnership
- Nature Metrics — NatureMetrics is a world-leading provider of biodiversity monitoring data, using environmental DNA (eDNA) surveys, metabarcoding and more.
Crédit Mutuel Innovation is the evergreen venture capital entity of Crédit Mutuel Equity (€3.5 billion in capital). We invest €1-20M in life science, digital and deeptech companies from seed to growth stages.We help bold and ambitious entrepreneurs to develop their strong growth potential with our worldwide enterprise ecosystem (our 350+portfolio companies, our abroad subsidiaries, 150+ largest global corporates and the best-in-class experts). Because it takes more than 5 years to build a Unicorn, we invest our own equity and ensure durable partnerships with visionary leaders.Today, the 350 companies in which we have invested generate a cumulative annual turnover of €50bn and create more than 250,000 jobs.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Series B
- Geography: France, United States, Canada
Investor stats
- Total investments: 88
- Round size: Series A $3.3M–$27M; Series B $6.7M–$43M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- iskn — Explore iskn's smart solutions for individuals and teams. Enhance creativity, productivity, and digital collaboration across workspaces worldwide.
- NEOBRAIN — Neobrain offers transformation support platforms that meet three needs within organisations: employee commitment and loyalty; simplification and fluidity of mobility; alignment of employee skills with the company's strategy.
- Biomemory — Biomemory creates DNA Drives for large corporates and administrations.
Octalfa is a France-based venture capital firm that offers a range of financial services.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: France
Investor stats
- Total investments: 18
- Round size: Seed $658k–$4.6M; Series A $1.5M–$3.7M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Mathym — Mathym - a nanotechnology company dedicated to the development, manufacturing and commercialization of nanomaterials and nanodispersions.
- ORPHELIA Pharma — ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus ondeveloping optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications.
- Sirius NeoSight — Sirius NeoSight is a biotech and pharmaceutical company that detects subclinical neo-cancers and provide treatment for it.
CEA Investissement (SA), founded (as CEA Valorisation) in 1999, is a subsidiary of the CEA, a major player in technological research, development and innovation. The central mission of CEA Valorisation is to create economic value based on technological innovations. To fulfill this mission, they have developed two main activities: Investmentin seed capital in innovative start-ups / start-ups active in the technology areas of CEA. The Licensing of advising companies and public laboratories of innovation in creative strategy development and marketing rights to patent or know-how belonging to the CEA, other research organizations or innovative companies. In addition, CEA contributes to the financing of national investment in seed technology (activity "Fund of Funds"), this activity is developed through particular Emertec management and funds managed by this company (FCPR Emertec 2 Emertec Energy and Environment), the FCPR managed by ACE Security Management SA, an investment company in seed priming Minatec SAS. Their areas of technological expertise are mainly micro-and nanotechnology, health technologies, the New Technologies for Information and Communication (NTIC), advanced materials and technologies for energy.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Semiconductor
- Stage:Seed, Series A
- Geography: France, Canada, United States
Investor stats
- Total investments: 45
- Round size: Seed $796k–$21M; Series A $1.4M–$13M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- iNGage — iNGage is a manufacturer of high-performance inertial MEMS navigation sensors for high-volume autonomous mobility markets
- STELLARIA — Stellaria is a 200 MWe molten salt reactor with 20-year autonomy, delivering safe, sustainable nuclear power without refueling.
- STELLARIA — Stellaria is reimagining sustainable rapid neutron nuclear energy.
we believe that top scientists and ambitious entrepreneurs can build a world where cutting-edge technologies shape the next generation of industry leaders.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical Device
- Stage:Series A, Series B
- Geography: France, United States, Israel
Investor stats
- Total investments: 95
- Round size: Series A $6M–$30M; Series B $7.7M–$58M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Fyteko — For a more sustainable agriculture
- ANYbotics — ANYbotics provides autonomous legged robots for industrial applications to provide high availability and reliability in automated routine inspections.
- Unseenlabs — Unseenlabs designs and develops a spectrum surveillance payload which is designed to detect and track non-cooperative vessels wherever they happen to be in the world.
Galion.exe invests in seed rounds and provide tools like guides, benchmarks, database, and open-source documents.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: France, The Netherlands, Germany
Investor stats
- Total investments: 24
- Round size: Seed $3.1M–$9.2M; Pre-Seed $1.1M–$9.4M; Series A $11M–$23M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- LETTRIA — Created in 2017 by Marian Szczesniak, Victor de la Salmonière and Charles Borderie, Lettria is one of the most advanced players in NLP (Natural Language Processing) in the French-speaking market. The team has developed a unique technology to achieve a higher level of accuracy and correction in French than the models created by English-speakingactors. Lettria aims to bring the processing of the French language as close as possible to human functioning by creating APIs based on French semantics and not on keywords. The Lettria team combines its scientific and technological skills with linguist profiles in order to deal as closely as possible with the specificities of the French language. They aim to make the use of NLP technologies accessible by offering high-performance proprietary libraries, high-quality educational content and demonstrating the benefits of using a 100% French model in all sectors of activity.
- Generare — Generare decodes microbial genomes to generate novel, high-quality molecular data for drug discovery. 200+ new molecules characterized and growing.
- Dialog — Dialog is the AI shopping assistant that transforms conversations into conversions, giving each shopper a tailored, in-store experience online.
EMERTEC’s experienced investment team has developed proven track record and has been able to develop close ties with major industrial players, many of them also being investors in their funds.These close ties are extremely valuable as to understand medium and long-term requirements of major order placers and high-level commercial opportunities.This brings visibility and confidence for entrepreneurs as well as for its investors.Their objective is to create value by turning ground-breaking technological innovations into commercial and financial successful companies.
Show more...Investment focus
- Industry: Energy, Software, Electronics
- Stage:Series A, Series B
- Geography: France, Canada, United States
Investor stats
- Total investments: 25
- Round size: Series A $1.4M–$6.8M; Series B $5.8M–$15M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- Ynsect — We are the world leader in insect ingredient production for animals, people, and plants. Our goal? To make the way we eat more nutritious and sustainable.
- eLichens — eLichens is a sensor tech company that takes sensor technology to the next level. Its mission is to empower people, companies, and government agencies to improve air quality, both indoor and outdoor.
- Osmia — Osmia SAS provides crop pollination services to improve yield and quality of agricultural production. Osmia intervenes in the context of specific problems on entomophilous or anemophilic pollination. Methodological approach and experience enables the company to find relevant solutions. It offers pollination studies and services for pre-base, baseor multiplication seeds. It also offers simple and efficient pollination services for arboriculture and optimize the yields and the quality of the productions of fruit trees.Osmia SAS was founded on 2014 and is headquartered in France.
High Tech, Low Carbon: crafting tomorrow, today. We finance innovation to make tomorrow happen today. Starquest is a Montefiore Company.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Seed, Series A
- Geography: France, Singapore, The Netherlands
Investor stats
- Total investments: 107
- Round size: Seed $288k–$7.7M; Series A $565k–$9.9M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $59M in 2021
Portfolio highlights
- auum — auum is a glass cleaning machine that optimizes the cleaning process and reduces its water consumption. It is also an economical cleaning technology designed to promote reusable containers at work. They offer service, maintenance, and replacement services.
- Heliup — Heliup is a company that creates and manufactures solar systems for huge building roofs for commercial and industrial buildings.
- Hydroclimat — Hydroclimat is a French DeepTech company using AI and climate data to help industries and authorities manage climate risks.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Kima Ventures promotes the growth of startups, supporting them in the fastest and most effective ways.
Show more...Investment focus
- Industry: Software, SaaS, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 523
- Round size: Seed $549k–$5.5M; Pre-Seed $560k–$4.4M; Series A $1.1M–$16M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Dialog — Dialog is the AI shopping assistant that transforms conversations into conversions, giving each shopper a tailored, in-store experience online.
- Explora Project — Explora Project is specializing in adventure travel and expeditions to the 4 corners of the planet and all environments.
- Flow Engineering — Requirements management, made collaborative
Venture capital for companies developing innovative therapeutics.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Medical
- Stage:Series A, Series B, Series C
- Geography: France, Switzerland, The Netherlands
Investor stats
- Total investments: 31
- Round size: Series A $12M–$122M; Series B $6.6M–$100M; Series C $23M–$125M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $205M in 2020
Portfolio highlights
- Araris Biotech — Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/orcell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.
- Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
- Engimmune Therapeutics — Engimmune Therapeutics - Engineering next-generation T cell receptor therapies
We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Pre-Seed, Seed, Series A
- Geography: United Kingdom, United States, India
Investor stats
- Total investments: 129
- Round size: Seed $1.2M–$9.5M; Pre-Seed $100k–$3.1M; Series A $6.6M–$220M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Maaind — Maaind is a leading neuroscience and AI company, creating an emotional intelligence layer that enables products and services to adapt to the user's emotions and stress levels in real-time, making experiences much more personalized and engaging.
- Messium — Messium's technology makes use of proprietary machine learning models and hyperspectral satellite constellations.
- Blocktorch — Blocktorch web3 observability platform provides real-time tracing, logging and monitoring for developers building decentralized applications and smart contracts. Try it for free.
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Private Equity
- Geography: France, United States, Germany
Investor stats
- Total investments: 177
- Round size: Series B $14M–$85M; Private Equity $110M–$247M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — raised $466M in 2022
Portfolio highlights
- MMI — The future of Microsurgery: microinstruments that expand the possibilities of surgical interventions. Wristed robotic microinstruments for unprecedented results in microsurgery.
- Amolyt Pharma — AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
- ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
Aurinvest is a venture capital fund it is managed and primarily funded by more than fifty entrepreneurs and business leaders, alongside with institutional investors. The company's goal is to invest in high growth companies or ventures which are on the edge of an exciting journey. It accompanies the founders in successfully carrying out theirplan. With this purpose, each holding is coached by two experienced professionals who stay in close contact with companies' management and who interface with Aurinvest's network.
Show more...Investment focus
- Industry: Software, E-Commerce, Biotechnology
- Stage:Series A, Series B
- Geography: France, United States, Belgium
Investor stats
- Total investments: 32
- Round size: Series A $1.4M–$5.8M; Series B $2.6M–$16M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Famoco — Empower your business with secure mobile solutions, from Android professional devices to remote and real-time monitoring of fleets.
- PathoQuest — PathoQuest provides biosafety assays based on next-generation sequencing (NGS) for biologics quality testing. GMP biotesting for biopharmaceuticals. Learn more.
- Evercontact — Let Evercontact connect the dots in your life by turning your emails into an always-updated address book!
BNP Paribas Développement is the investment arm of BNP Paribas that specializes in SME development. It specializes in second stage, mezzanine, bridge, acquisition, leveraged buyouts, management buyouts, recapitalization, special situations, and privatizations transactions.The firm considers investments in manufacturing, service industries,medicine, electronics, energy, chemistry, new materials, industrial automations, industrial goods and services, transportation, consumer goods, commerce and distribution, buildings and public works, wholesale retail, biotechnology, telecommunications, and information technology sectors.BNP Paribas Développement was established in 1988 and is based in Paris, France.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed
- Geography: France, Germany, The Netherlands
Investor stats
- Total investments: 134
- Round size: Seed $2M–$10M; Series A $3.8M–$23M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Proteor — Proteor offers a complete range of high quality products and services to the O&P world, through more than 60 clinics.
- Endodiag — Endodiag specializes in the development of products and services that improves the diagnosis of endometriosis. Endodiag takes part in endometriosis research by developing diagnosis solutions focused on patient screening and individual endometriosis characteristics.
- BeFC Bioenzymatic Fuel Cells — Miniature batteries are complex, expensive and unecological to collect and recycle. Our thin, light-weight and flexible paper-based biofuel cells are biodegradable, environmentally friendly and economically viable.
Nord France Amorçage is a regional co-investment fund, exclusively supported by the Hauts-de-France Region. This seed fund has been involved since 2013 in financing innovative businesses that create jobs and add value to the region. In 6 years, NFA has more than 50 participants spread across the region.
Show more...Investment focus
- Industry: Software, Information Technology, Medical
- Stage:Seed, Series A
- Geography: France, United States
Investor stats
- Total investments: 32
- Round size: Seed $329k–$2.5M; Series A $1.1M–$25M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- NeoCem — NeoCem creates, manufactures, and promotes a variety of low-carbon cements for the building industry. They have developed a novel procedure that permits the utilization of raw materials sourced from recovery sectors.
- Vaxinano — Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder.
- Energo — To reduce global warming, Energo has developed an innovative technology to convert gases into molecules of interested at high added value
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 121
- Round size: Series A $5.7M–$55M; Series B $14M–$88M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Kreaxi is a management company specializing for over 30 years in investing in the capital of innovative and technological startups with high potential.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Series A
- Geography: France, Italy, Switzerland
Investor stats
- Total investments: 62
- Lead/follow: no public data
Portfolio highlights
- QiOVA — Founded in 2011, QiOVA develops and markets the world's fastest laser marking and micromachining solutions thanks to the pioneering integration of programmable multibeam technology.
- B2eBike — B2ebike provides comprehensive electric bicycle fleet (VAE) solutions for businesses and communities. The best strategy to convert to a soft form of transportation.
- Diamfab — Diamond semiconductor - DIAMFAB - Our project aims to manufacture a sustainable carbon-based diamond semiconductor !
The private equity fund focused on adding high value.IXO Private Equity is a private equity management company recognized, approved and authorized by the Financial Market Authorities (AMF) operating under the number GP03018.IXO Private Equity is the most important independent regional private equity General Partner in France.The companymanages French General Private Equity Investment Funds (known in France as F.C.P.R.), Local Private Equity Investment Fund (known in France as F.I.P.), and Private Equity Investment Funds for Innovation (F.C.P.I.) to meet the equity needs for the best companies in Western and Southern France.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Private Equity, Series A
- Geography: France, United States, Canada
Investor stats
- Total investments: 64
- Lead/follow: no public data
Portfolio highlights
- Indy — Indy offers end-to-end and advanced AI-powered accounting software. Indy is an accounting robot that aims to automate the accounting of freelancers and professionals. It is an accounting robot for the liberal professions. It automates the management of accounting, recovers bank entries to turn them into accounting lines, and sends tax returnsdirectly to an AGM.It was founded in 2016 as Georges by Côme Fouques, Pablo Larvor, Romain Koenig, and Adrien Plat to simplify independent accounting, which is certainly simple but repetitive and time-consuming.
- Wecasa — Wecasa is a data-driven marketplace that revolutionizes care services by focusing on user experience for customers and professionalsWecasa's mission is to make care services simple and accessible for a better quality of life. Through its app, users can book in seconds a reliable Professional for care services at home: wellness (haircut,beauty, massage), cleaning, and childcare. Available in Paris, top cities in France, London, and more European cities to come. Wecasa is proud to help 100.000+ customers and increase the business of 3000 independent professionals.
- Farmitoo — Farmitoo is an online purchase of farm equipment directly from manufacturers.
Biotechnology Investor funding in France at a glance
Stats across 863 deals from 852 investors.
Access all 852 investors in France Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in France investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 852 investors investing in France Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!